Imaging of VMAT2 binding sites in the brain by 18F-AV-133: The effect of a pseudo-carrier

Nuclear Medicine and Biology

Volumn 39, Issue 7, 2012, Pages 897-904

  Zhu, Lin ^a,b   Qiao, Hongwen ^a,b   Lieberman, Brian P ^b   Wu, Jingxiao ^a   Liu, Yajing ^a,b,c   Pan, Zhongyun ^a,c   Ploessl, Karl ^b   Choi, Seok Rye ^e   Chan, Piu ^c,d   Kung, Hank F ^a,b  

^a BEIJING NORMAL UNIVERSITY   (China)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d Wincon Theracells Biotechnologies Co Ltd Nanning   (China)

^e AVID RADIOPHARMACEUTICALS   (United States)

Author keywords

Brain imaging and pseudo carrier effect; Parkinson's disease; PET imaging; Vesicular monoamine transporter 2

Indexed keywords

9 HYDROXYPROPYL DIHYDROTETRABENAZINE F 18; AV 149; FLORBENAZINE F 18; OXIDOPAMINE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; VESICULAR MONOAMINE TRANSPORTER 2;

ANALYTICAL EQUIPMENT; ANIMAL TISSUE; ARTICLE; AUTOPSY; AUTORADIOGRAPHY; BINDING SITE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG PURITY; EX VIVO STUDY; HAPLORHINI; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTERMETHOD COMPARISON; NEUROIMAGING; NONHUMAN; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PURIFICATION; RADIOCHEMISTRY; RAT; SOLID PHASE EXTRACTION; TISSUE SECTION;

ANIMALS; BINDING SITES; BIOLOGICAL TRANSPORT; BRAIN; DRUG CARRIERS; FLUORINE RADIOISOTOPES; HAPLORHINI; HUMANS; MALE; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; RATS; TETRABENAZINE; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 84866005204     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2012.05.002     Document Type: Article

References (39)

1. Brooks D.J., Pavese N. Imaging biomarkers in Parkinson's disease. Prog Neurobiol 2011, 95:614-628.
2. Pavese N. Pet studies in Parkinson's disease motor and cognitive dysfunction. Parkinsonism Relat Disord 2012, 18(Suppl. 1):S96-S99.
3. Brooks D.J. Parkinson's disease: diagnosis. Parkinsonism Relat Disord 2012, 18(Suppl. 1):S31-S33.
4. Seibyl J.P. Single-photon emission computed tomography and positron emission tomography evaluations of patients with central motor disorders. Semin Nucl Med 2008, 38:274-286.
5. 11C]PE2I. Eur J Nucl Med Mol Imaging 2007, 34:667-678.
6. Volkow N.D., Ding Y.S., Fowler J.S., et al. A new PET ligand for the dopamine transporter: studies in the human brain. J Nucl Med 1995, 36:2162-2168.
7. 11C]tetrabenazine to vesicular monoamine transporters in mouse brain. Life Sci 1992, 51:593-600.
8. Kilbourn M.R. In vivo radiotracers for vesicular neurotransmitter transporters. Nucl Med Biol 1997, 24:615-619.
9. Bohnen N.I., Albin R.L., Koeppe R.A., et al. Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease. J Cereb Blood Flow Metab 2006, 26:1198-1212.
10. Lee C.S., Schulzer M., de la Fuente-Fernandez R., et al. Lack of regional selectivity during the progression of Parkinson disease: implications for pathogenesis. Arch Neurol 2004, 61:1920-1925.
11. Bohnen N.I., Gedela S., Kuwabara H., et al. Selective hyposmia and nigrostriatal dopaminergic denervation in Parkinson's disease. J Neurol 2007, 254:84-90.
12. Boileau I., Rusjan P., Houle S., et al. Increased vesicular monoamine transporter binding during early abstinence in human methamphetamine users: is vmat2 a stable dopamine neuron biomarker?. J Neurosci 2008, 28:9850-9856.
13. 11C]methylphenidate binding in tourette syndrome. Neurology 2009, 72:1390-1396.
14. Goswami R., Ponde D., Kung M., Hou C., Kilbourn M., Kung H. Fluoroalkyl derivatives of dihydrotetrabenazine as positron emission tomography imaging agents targeting vesicular monoamine transporters. Nucl Med Biol 2006, 33:685-694.
15. Kung M., Hou C., Goswami R., Ponde D., Kilbourn M., Kung H. Characterization of optically resolved 9-fluoropropyl-dihydrotetrabenazine as a potential PET imaging agent targeting vesicular monoamine transporters. Nucl Med Biol 2007, 34:239-246.
16. 18F]fluoroalkyl derivatives of dihydrotetrabenazine in rat and monkey brain. Nucl Med Biol 2007, 34:233-237.
17. 18F-AV-133. J Nucl Med 2010, 51:223-228.
18. Villemagne V.L., Okamura N., Pejoska S., et al. In vivo assessment of vesicular monoamine transporter type 2 in dementia with lewy bodies and Alzheimer disease. Arch Neurol 2011, 68:905-912.
19. Brooks D. Imaging approaches to Parkinson disease. J Nucl Med 2010, 51:596-609.
20. 18F epoxide derivative of tetrabenazine. Nucl Med Biol 2008, 35:825-837.
21. 18F-FP-(+)-DTBZ: a potential PET ligand for studying diabetes mellitus. J Nucl Med 2008, 49:1171-1176.
22. 18F]AV-133: a PET imaging agent for vesicular monoamine transporter 2. Nucl Med Biol 2010, 37:133-141.
23. 68Ga: practical aspects of radiolabelling. Contrast Media Mol Imaging 2011, 6:492-498.
24. 18F]fluoroethyl)-l-tyrosine based on a cartridge purification method. Nucl Med Biol 2011, 38:653-658.
25. Zhou X., Qiao J., Yin W., Zhu L., Kung H.F. Study the effect of a pseudo-carrier on pharmacokinetics of 9-fluoropropyl-(+)-dihydrotetrabenazine in rat plasma by ultra-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2011, 879:505-510.
26. Chen M.K., Kuwabara H., Zhou Y., et al. Vmat2 and dopamine neuron loss in a primate model of Parkinson's disease. J Neurochem 2008, 105:78-90.
27. 18F-AV-133) summed uptake measurements. Nucl Med Biol 2011, 38:1149-1155.
28. Tatsch K. Positron emission tomography in diagnosis and differential diagnosis of Parkinson's disease. Neurodegener Dis 2010, 7:330-340.
29. Reichmann H. Clinical criteria for the diagnosis of Parkinson's disease. Neurodegener Dis 2010, 7:284-290.
30. Appel-Cresswell S., de la Fuente-Fernandez R., Galley S., McKeown M. Imaging of compensatory mechanisms in Parkinson's disease. Curr Opin Neurol 2010, 23:407-412.
31. Pavese N., David J.Brooks Imaging neurodegeneration in Parkinson's disease. Biochim Biophys Acta 2009, 1792:722-729.
32. 2: a convenient synthesis of 2-deoxy-2-fluoro-d-glucose. J Org Chem 1977, 42:2341.
33. 14C]-2-deoxy-2-fluoro-d-glucose. J Label Compd Radiopharm 1978, 14:175-183.
34. 18F]fluoro-d-glucose. J Nucl Med 1981, 22:376-380.
35. 18F]-fluoro-2-deoxy-d-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 1986, 27:235-238.
36. 18F-fluorination. Nucl Med Biol 2002, 29:275-279.
37. 18F]FDG by HPLC with UV detection. Nucl Med Biol 2005, 32:907-912.
38. 18FDG preparations and detection of the chemical impurity 2-deoxy-2-chloro-d-glucose. Int J Rad Appl Instrum A 1992, 43:1313-1322.
39. 18F]FDG preparation by high-performance liquid chromatography with uv detection. Nucl Med Biol 2008, 35:239-244.